enlightenVue Awarded Chinese Patent for Micro-Endoscope Platform

enlightenVue Inc.’s core technology is now protected in China.

The company has been awarded a patent from the Middle Kingdom for the technology encompassing its surgiVue single-use micro-endoscope platform. “The patent covers the key innovation in our micro-endoscope, an expandable tip that provides access for multiple instruments within the industry’s smallest working diameter, along with superior optics,” said Giacomo Basadonna, M.D., Ph.D. “The endoscope’s dual functionality, along with the small working channel, allows its use in a wide range of applications with no patient cross-contamination risk.”

The patented technology enables clinicians to use the endoscope in diagnostic and therapeutic applications in a single procedure through two working channels in a two-millimeter working diameter. Based on its small diameter size, the company’s micro endoscope platform allows the device to be used in applications that have not been accessible to other endoscopes and conventional endoscopes such as hepatobiliary; ear, nose and throat; obstetrics and gynecology; and orthopedics. In addition, the endoscope also has potential utility in percutaneous and intra-surgical settings.
 
The enlightenVue technology is protected by three patent families. Besides the Chinese patent, there are four issued U.S. patents, including the core patent, with additional U.S. and international patents pending.
 
enlightenVue has developed a single-use micro-endoscope platform with the industry’s smallest diameter (2mm) with multiple working channels, which can be used in a single procedure for both diagnostic and therapeutic interventions. The surgiVue platform’s dual functionality is based on an expandable tip to provide access for multiple instruments along with superior optics. The system, which has 510(k) clearance, enables use across multiple specialties and healthcare settings to provide significant benefits to patients, clinicians, and the healthcare system with no cross-patient risk of endoscopic infection.